NCT07006688 2026-02-18A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServierPhase 1 Recruiting30 enrolled
NCT02074839 2025-06-08Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationServierPhase 1 Recruiting291 enrolled 3 FDA
NCT05907057 2025-04-11An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.ServierPhase 3 Recruiting245 enrolled